Ocrelizumab

Introduction Overview

Generic Name

ocrelizumab

Brand Name

Ocrevus

Dosage Form

intravenous infusion, subcutaneous injection

Drug Class

CD20 monoclonal antibodies

Pharmacokinetics

Absorption:
Ocrelizumab is a monoclonal antibody administered primarily via intravenous infusion as Ocrevus and subcutaneous injection as Ocrevus Zunovo. Due to its high molecular weight and protein structure, absorption through traditional enteral routes is not feasible, necessitating parenteral administration. IV infusion delivers ocrelizumab directly into systemic circulation, ensuring complete bioavailability. The recently FDA-approved subcutaneous formulation, Ocrevus Zunovo, combines ocrelizumab with hyaluronidase to facilitate dispersion and absorption through subcutaneous tissues, achieving bioavailability consistent with systemic delivery. Clinical pharmacokinetic studies confirm that the subcutaneous route yields therapeutic plasma concentrations suitable for effective dosing, with approximately twice yearly administration maintaining steady state.

Distribution:
Following administration, ocrelizumab primarily remains within the vascular and interstitial spaces due to its large size (~145 kDa) and hydrophilic nature. The volume of distribution is low, approximating plasma volume, reflecting limited tissue penetration. Ocrelizumab targets B cells expressing the CD20 antigen; thus, a fraction of the drug binds to B cells in lymphoid tissues, blood, and perivascular sites. Pharmacodynamic effects correlated with pharmacokinetics show rapid and sustained depletion of B cells in peripheral blood. Ocrelizumab does not significantly cross the blood-brain barrier; however, central nervous system benefits are proposed due to peripheral immune modulation.

Metabolism:
As a humanized monoclonal antibody, ocrelizumab undergoes proteolytic catabolism rather than hepatic metabolism typical of small molecules. The drug is degraded enzymatically by reticuloendothelial system cells into small peptides and amino acids, which are recycled or eliminated. This catabolic pathway mitigates concerns regarding cytochrome P450 enzyme interactions. Consequently, ocrelizumab’s metabolism is not significantly affected by liver enzyme inducers or inhibitors, nor does it alter hepatic enzyme activity.

Elimination:
Elimination of ocrelizumab occurs via two main pathways: target-mediated drug disposition and nonspecific proteolytic catabolism. The antibody is cleared following internalization and degradation after binding to CD20-positive B cells. Additionally, unbound ocrelizumab undergoes non-specific clearance by the reticuloendothelial system. The terminal half-life is approximately 26 days, supporting dosing intervals of six months for maintenance therapy. Renal excretion is negligible due to the drug's size and nature. Immunogenicity is low, and anti-drug antibodies have not been shown to significantly alter clearance or efficacy.

Clinical pharmacokinetic studies demonstrated dose-proportional kinetics over the therapeutic range with interpatient variability influenced mainly by body weight. Age, gender, and mild to moderate renal or hepatic impairment do not significantly affect pharmacokinetics. However, careful monitoring is warranted in patients with concomitant immunosuppressive therapies due to potential additive immunosuppression effects.

Dosage Forms

Available Dosage Forms:
Ocrevus is supplied as a sterile, preservative-free, clear to slightly opalescent, colorless to pale yellow solution for intravenous infusion in single-dose vials. The commercially available vial contains 300 mg of ocrelizumab in 10 mL (30 mg/mL concentration).
Ocrevus Zunovo is a subcutaneous injectable formulation combining ocrelizumab with hyaluronidase to facilitate absorption and dispersion in subcutaneous tissue; it is administered as a 3.5 mL injection containing 120 mg of ocrelizumab and 15,000 units of hyaluronidase per dose. This approved formulation facilitates shorter administration time (approximately 10 minutes).

Dosages for Adults and Adolescents:
The initial dosing regimen for Ocrevus intravenous infusion consists of two 300 mg doses given two weeks apart. Each infusion is administered over approximately 2 hours and 30 minutes. Following this loading phase, maintenance therapy consists of 600 mg administered as a single intravenous infusion every 6 months, infused over 2 to 3.5 hours, depending on the prescribing healthcare provider's recommendations and patient tolerability.
For Ocrevus Zunovo subcutaneous injections, the regimen is two initial administrations 2 weeks apart (120 mg each), followed by maintenance doses every 6 months. This provides an effective alternative to intravenous infusion for maintenance therapy.

Specific Patient Populations:
Dosing adjustments based on age, gender, renal or hepatic impairment are not necessary as pharmacokinetic studies show no clinically significant effects. The drug is approved for adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive MS, as well as for primary progressive multiple sclerosis in adults. Pediatric safety and efficacy have not been established, and Ocrevus is not currently approved for pediatric use.
Pregnant and breastfeeding patients should use contraception during treatment and for at least 6 months after the last infusion or injection due to unknown risks. Immunization with live vaccines should be avoided concurrently.

Clinical guidelines emphasize pre-medication with corticosteroids and antihistamines prior to every infusion or injection to mitigate infusion/injection-related reactions. Patients are also monitored closely during and at least one hour after administration. Due to risk of infections and immune suppression, baseline hepatitis B screening and immunoglobulin levels are recommended prior to initiation.

Mechanism Of Action

Ocrevus (ocrelizumab) is a humanized monoclonal antibody specifically designed to target the CD20 antigen found on the surface of B-lymphocytes, a subset of white blood cells implicated in the pathogenesis of multiple sclerosis (MS). By binding selectively to CD20, ocrelizumab leads to targeted depletion of these B cells while sparing stem cells and plasma cells which do not express CD20, preserving essential immune functions such as antibody production.

The binding of ocrelizumab to CD20 initiates multiple immune-mediated mechanisms of B-cell destruction, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and induction of apoptosis. ADCC involves recruitment of natural killer (NK) cells and macrophages that recognize the Fc region of the antibody, leading to lysis of the B cell. Complement activation results in formation of the membrane attack complex, causing cell lysis. Collectively, these mechanisms result in rapid and sustained depletion of circulating and tissue-resident CD20-positive B cells.

At the cellular and molecular level, B-cell depletion attenuates MS pathology by reducing antigen presentation to autoreactive T cells, decreasing pro-inflammatory cytokines, and lowering the production of pathogenic autoantibodies that contribute to demyelination and neurodegeneration. Importantly, this selective depletion modulates adaptive immunity without broadly suppressing innate immunity, potentially preserving overall host defense.

Clinical studies confirm that ocrelizumab decreases the frequency of MS relapse, diminishes new lesion formation on MRI, and slows progression of disability in both relapsing and primary progressive types of MS. Compared to other disease-modifying therapies, such as interferon-beta or other monoclonal antibodies targeting different immune components, ocrelizumab’s specificity for CD20-positive B cells offers a distinct immunomodulatory profile with an effective balance of efficacy and safety. Continuous research supports the central role of B cells in MS pathophysiology and validates CD20 as a therapeutic target, underscoring the clinical benefits observed with Ocrevus therapy.

Pharmacological Actions

Selective depletion of CD20-positive B lymphocytes through antibody-mediated cytolysis.
Reduction of antigen presentation to autoreactive T cells, decreasing neuroinflammation.
Inhibition of pro-inflammatory cytokine secretion by B cells, mitigating immune-mediated tissue damage.
Decreased autoantibody production involved in demyelination processes.
Modulation of adaptive immune responses without global immunosuppression.
Slowing of neurological disability progression in multiple sclerosis patients.
Reduction in the frequency and severity of MS relapses.
Prevention of formation of new inflammatory lesions in the central nervous system.
Improvement in MRI markers indicative of disease activity.
Provision of an alternative to traditional immunomodulatory therapies with a novel mechanism.
Sparing of plasma cells preserves humoral immunity to previous infections and vaccinations.
Minimal impact on innate immune cells such as macrophages and neutrophils.
Immunomodulation demonstrated to reduce central nervous system tissue injury.
Cytolytic activity mediated via ADCC, CDC and apoptosis induction in B cells.
Enables treatment of both relapsing and primary progressive forms of multiple sclerosis.

Therapeutic Or Clinical Uses

Treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome and relapsing-remitting MS.
Management of active secondary progressive multiple sclerosis in adult patients.
Treatment of primary progressive multiple sclerosis (PPMS) in adults.
Reduction of relapse frequency and severity in RMS patients.
Slowing of disability progression related to multiple sclerosis.
Reduction of new or enlarging MRI lesions indicative of inflammatory disease activity.
An option for patients who have contraindications or intolerance to other disease-modifying therapies.
Use as a maintenance therapy with biannual dosing schedules.
Potential utility in patients who require targeted B-cell depletion without systemic chemotherapy effects.
FDA-approved for both relapsing and progressive disease forms offering broader therapeutic coverage.
Adjunct to reduce neuroinflammatory damage and preserve neurological function.
Applicable in patients with active disease as defined by clinical or MRI parameters.
Contributes to immune modulation without total immunosuppression, preserving host defenses.
Alternative administration as intravenous infusion or subcutaneous injection for patient convenience.
Improvement of patient quality of life by reducing disease activity and progression.

Side Or Adverse Effects

Infusion reactions including rash, itching, flushing, throat irritation, headache, and shortness of breath.
Upper respiratory tract infections such as stuffy nose, sneezing, sore throat, and common cold symptoms.
Lower respiratory tract infections including bronchitis and pneumonia.
Skin infections and herpes virus infections (cold sores, shingles, genital sores).
Serious allergic reactions including anaphylaxis and severe infusion-related hypersensitivity reactions.
Progressive multifocal leukoencephalopathy (PML), a rare but potentially fatal brain infection.
Hepatitis B virus reactivation potentially leading to severe liver damage or failure.
Decreased immunoglobulin levels, leading to increased infection risk.
Gastrointestinal symptoms such as diarrhea and abdominal pain.
Fatigue and dizziness reported during or after infusion.
Nausea and vomiting in some patients.
Hives and other skin rashes post-infusion or injection.
Potential for mood or behavioral changes, confusion, and neurological symptoms.
Injection site reactions with subcutaneous administration.
Possible increased risk of malignancies, though data are still being evaluated.

Precautions

Pre-treatment screening for active or prior hepatitis B virus infection is mandatory.
Avoid live or live-attenuated vaccines during treatment and until immune recovery.
Use caution with concurrent immunosuppressive or immune-modulating therapies to reduce infection risk.
Inform healthcare providers of any active infection prior to administration; delay treatment if present.
Pre-medicate with corticosteroids, antihistamines, and antipyretics to reduce infusion reactions.
Monitor patients closely during and after infusions for hypersensitivity or infusion reactions.
Advise patients to report symptoms suggestive of infection immediately, including fever and chills.
Pregnant women should use contraception during and for 6 months after therapy; safety in pregnancy is not established.
Caution advised in patients with a history of inflammatory bowel disease or colitis.
Regular monitoring of immunoglobulin levels during therapy to detect hypogammaglobulinemia.
Assess for neurological changes suggestive of PML; discontinue treatment if suspected.
Educate patients about signs of hepatitis B reactivation.
Avoid initiating therapy in patients with active infection or recent live vaccinations.
Use of alternate contraception methods during pregnancy planning and lactation advised.
Delaying or discontinuing therapy may be necessary based on infection or adverse reaction severity.

Warnings

Serious and potentially life-threatening infusion reactions requiring immediate medical intervention.
Risk of serious infections including upper and lower respiratory tract infections and herpes virus reactivation.
Potential for reactivation of hepatitis B virus leading to liver failure or death.
Possibility of developing progressive multifocal leukoencephalopathy (PML), a rare fatal encephalitis.
Decreased immunoglobulin levels may increase susceptibility to infections.
Patients with active hepatitis B infection must not receive Ocrevus.
Live vaccines contraindicated during therapy and until immune competence is re-established.
Delayed hypersensitivity reactions may occur up to 24 hours post-infusion requiring vigilant monitoring.
Risk of malignancy has been noted but causality remains under investigation.
Monitor closely for neurological symptoms suggestive of PML or MS progression.
Ocrevus may interfere with immune response to vaccinations.
Pregnancy safety has not been established; potential fetal harm cannot be excluded.
Healthcare providers should be prepared to manage severe allergic or anaphylactic reactions.
Patients should inform providers of any previous allergic reactions to ocrelizumab or similar agents.
Caution when administering to patients with compromised immune systems or concomitant immunosuppressive therapy.

Contraindication

Known hypersensitivity to ocrelizumab or any excipient of the formulation.
Active hepatitis B virus infection due to risk of viral reactivation and hepatic complications.
History of severe or life-threatening infusion or injection reactions to ocrelizumab.
Use during pregnancy unless clearly needed and benefits outweigh risks due to unknown fetal safety.
Concurrent administration of live or live-attenuated vaccines is contraindicated during therapy.
Patients with severe active infections until resolution of the infection.
Known immunodeficiency syndromes compromising patient safety.
Unapproved use in pediatric populations as safety and efficacy are not established.
Use in patients with history of hypersensitivity to other anti-CD20 therapies to be approached with caution.
Ocrevus should not be administered without appropriate premedication to reduce infusion reactions.
Contraindicated if patient participates in clinical trials involving conflicting investigational immunotherapies.

Drug Interactions

Concomitant use with other immunosuppressive or immune-modulating therapies increases infection risk.
No significant interaction with cytochrome P450 substrates observed due to proteolytic metabolism.
May interfere with the effectiveness of live vaccines; avoid co-administration.
No known significant interactions with commonly used concomitant medications in MS patients.
Potential additive immunosuppression with other monoclonal antibodies or chemotherapy agents.
No clinically relevant pharmacokinetic interactions with antihistamines or corticosteroids used for premedication.
Use caution when combining with other biologic agents targeting B cells or immune pathways.
Interactions with antiviral agents are not well characterized but vigilance for infections is warranted.
No reported interactions affecting pharmacodynamics or dosing schedules.
Patients should inform healthcare providers of all supplements or herbal products due to unknown interaction potential.
Monitoring is recommended when switching between B-cell therapies to avoid overlapping immunosuppression.
Concurrent vaccination with inactivated vaccines may have reduced effectiveness.
No documented interaction with commonly prescribed symptomatic treatments for MS.
May alter immune response impacting the pharmacological effect of live vaccines.
Limited data exists on interactions with new multiple sclerosis therapies; clinical judgment advised.

Preparations Of The Drug

Ocrevus is supplied as a sterile, preservative-free intravenous infusion solution in a single-dose vial format containing 300 mg ocrelizumab per 10 mL vial (30 mg/mL).
The solution must be diluted prior to administration using appropriate infusion equipment.
Ocrevus Zunovo is a subcutaneous injectable preparation containing ocrelizumab 120 mg combined with hyaluronidase (15,000 units) to facilitate subcutaneous absorption.
Both formulations are manufactured by Genentech, Inc., Roche Group.
Inactive ingredients include glacial acetic acid, polysorbate 20, sodium acetate trihydrate, and trehalose dihydrate to maintain stability.
Vials are stored refrigerated between 2°C and 8°C (36°F to 46°F), protected from light and should not be frozen or shaken.
Prepared infusion solutions can be stored refrigerated up to 24 hours or at room temperature up to 8 hours prior to administration, including infusion time.
Unused portions of diluted infusions must be discarded appropriately if not used within recommended storage duration.
The intravenous infusion is administered over 2 to 3.5 hours depending on dose and patient tolerance.
Subcutaneous formulation is administered as a 3.5 mL injection over approximately 10 minutes.
Each treatment course requires premedication with corticosteroids and antihistamines to minimize infusion or injection reactions.
Packaging includes detailed prescribing information, usage instructions, and safety guidelines.
The drug carries an FDA J-code of J2350 for billing and reimbursement purposes.
NDC code for Ocrevus vial is 50242-150-01 (10 digit format) or 50242-0150-01 (11 digit format).
Handling precautions include use of aseptic technique and appropriate disposal of used vials and infusion sets.